PHAXIAM Therapeutics S.A.
PHAXIAM Therapeutics S.A., a clinical-stage biopharmaceutical company, focuses on developing bacteriophage-based therapies for severe resistance infections in France. The company develops and commercializes red cell-based therapies for cancers and orphan diseases. It develops anti-infectious therapies based on the use of bacteriophages (phages) to treat infections caused by Escherichia coli (E.co… Read more
PHAXIAM Therapeutics S.A. (PHXM) - Total Assets
Latest total assets as of June 2024: €39.11 Million EUR
Based on the latest financial reports, PHAXIAM Therapeutics S.A. (PHXM) holds total assets worth €39.11 Million EUR as of June 2024.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
PHAXIAM Therapeutics S.A. - Total Assets Trend (2010–2023)
This chart illustrates how PHAXIAM Therapeutics S.A.’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
PHAXIAM Therapeutics S.A. - Asset Composition Analysis
Current Asset Composition (December 2023)
PHAXIAM Therapeutics S.A.'s total assets of €39.11 Million consist of 31.6% current assets and 68.4% non-current assets.
| Asset Category | Amount (EUR) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | €10.47 Million | 20.4% |
| Accounts Receivable | €103.00K | 0.2% |
| Inventory | €4.96 Million | 9.7% |
| Property, Plant & Equipment | €3.90 Million | 7.6% |
| Intangible Assets | €21.36 Million | 41.6% |
| Goodwill | €9.62 Million | 18.8% |
Asset Composition Trend (2010–2023)
This chart illustrates how PHAXIAM Therapeutics S.A.'s asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: PHAXIAM Therapeutics S.A.'s current assets represent 31.6% of total assets in 2023, an increase from 0.0% in 2010.
- Cash Position: Cash and equivalents constituted 20.4% of total assets in 2023, down from 48.4% in 2010.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 59.0% of total assets, an increase from 1.0% in 2010.
- Asset Diversification: The largest asset category is intangible assets at 41.6% of total assets.
PHAXIAM Therapeutics S.A. Competitors by Total Assets
Key competitors of PHAXIAM Therapeutics S.A. based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
MedPacto Inc
KQ:235980
|
Korea | ₩51.58 Billion |
|
2H0
F:2H0
|
Germany | €15.27 Million |
|
Shenzhen CAU Technology Co Ltd
SHE:000004
|
China | CN¥260.55 Million |
|
Pacific Shuanglin Bio pharmacy Co Ltd
SHE:000403
|
China | CN¥9.58 Billion |
|
Nanhua Bio Medicine Co Ltd
SHE:000504
|
China | CN¥841.96 Million |
|
Jiangsu Sihuan Bioengineering Co Ltd
SHE:000518
|
China | CN¥509.14 Million |
|
Chengzhi Shareholding Co Ltd
SHE:000990
|
China | CN¥27.52 Billion |
|
Hualan Biological EngineeringInc
SHE:002007
|
China | CN¥16.27 Billion |
PHAXIAM Therapeutics S.A. - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Lower asset utilization - PHAXIAM Therapeutics S.A. generates 0.03x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Negative ROA - PHAXIAM Therapeutics S.A. is currently not profitable relative to its asset base.
PHAXIAM Therapeutics S.A. - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 0.38 | 1.78 | 5.91 |
| Quick Ratio | 0.32 | 1.78 | 5.90 |
| Cash Ratio | 0.09 | 1.45 | 0.00 |
| Working Capital | €-9.62 Million | € 13.53 Million | € 91.64 Million |
PHAXIAM Therapeutics S.A. - Advanced Valuation Insights
This section examines the relationship between PHAXIAM Therapeutics S.A.'s asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 0.03 |
| Latest Market Cap to Assets Ratio | 0.01 |
| Asset Growth Rate (YoY) | 12.0% |
| Total Assets | €51.31 Million |
| Market Capitalization | $625.66K USD |
Valuation Analysis
Below Book Valuation: The market values PHAXIAM Therapeutics S.A.'s assets below their book value (0.01 x), which may indicate investor concerns about asset quality or future growth.
Rapid Asset Growth: PHAXIAM Therapeutics S.A.'s assets grew by 12.0% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for PHAXIAM Therapeutics S.A. (2010–2023)
The table below shows the annual total assets of PHAXIAM Therapeutics S.A. from 2010 to 2023.
| Year | Total Assets | Change |
|---|---|---|
| 2023-12-31 | €51.31 Million | +12.00% |
| 2022-12-31 | €45.81 Million | -31.39% |
| 2021-12-31 | €66.77 Million | -16.96% |
| 2020-12-31 | €80.40 Million | -32.18% |
| 2019-12-31 | €118.55 Million | -29.37% |
| 2018-12-31 | €167.84 Million | -14.04% |
| 2017-12-31 | €195.26 Million | +334.23% |
| 2016-12-31 | €44.97 Million | -15.16% |
| 2015-12-31 | €53.00 Million | +30.53% |
| 2014-12-31 | €40.61 Million | +126.23% |
| 2013-12-31 | €17.95 Million | +76.94% |
| 2012-12-31 | €10.14 Million | +105.30% |
| 2011-12-31 | €4.94 Million | -24.73% |
| 2010-12-31 | €6.56 Million | -- |